This podcast, Episode [32], introduced with the "DDReg Knowledge capsule" greeting, provides a deep dive into the complexities of pharmaceutical registration in Brazil. It explores the central role of ANVISA (National Health Surveillance Agency) and the specific regulatory pathways designed to accelerate market entry, such as Priority Review and the Reliance and Expedited Pathway. The discussion covers critical technical requirements, including the use of the Common Technical Document (CTD) format for dossiers and the shift toward completely paperless filing via Datavisa. Furthermore, the podcast highlights strategic approaches for success, such as leveraging CADIFA for API GMP certification and navigating challenges like language barriers and complex clinical trial timelines.For More Visit Blog -:https://resource.ddregpharma.com/blogs/drug-registration-process-in-brazil/

Welcome to this episode of the DDReg Knowledge Capsule, Episode [31] where we explore the critical role of Standard Operating Procedures (SOPs) as the foundation of a reliable pharmacovigilance (PV) system. This discussion highlights how well-written SOPs transform global regulatory requirements from agencies such as the EMA, FDA, and CDSCO into actionable workflows that ensure patient safety and data integrity.

📢 DDReg Knowledge Capsule – Episode [30]This podcast provides an in-depth analysis of Indonesia's regulatory landscape, the largest pharmaceutical market in Southeast Asia, with a population exceeding 270 million. It details the methodical and documentation-intensive drug registration process managed by the National Agency of Drug and Food Control (BPOM). Key insights include the mandatory requirement for a local registration holder, the specific structure of the ACTD dossier, and technical requirements such as Zone IVb stability data and Bahasa Indonesia labeling. The guide is an essential resource for understanding the complexities of obtaining a Nomor Izin Edar (NIE) and managing long-term pharmacovigilance obligations.For More Visit our Blog -:https://resource.ddregpharma.com/blogs/bpom-drug-registration-indonesia-market-entry-guide/

📢 DDReg Knowledge Capsule – Episode [29]The shift in global healthcare as digital tools move from experimental pilots to core national infrastructure. It highlights the collaborative roles of the World Health Organisation (WHO), which defines the strategic policy framework, and the Global Initiative on Digital Health (GIDH), which manages the practical implementation and funding. The 2027 strategy aims to bridge the digital divide by ensuring that healthcare technology is interoperable, ethical, and secure across all income levels. Key focus areas include the governance of artificial intelligence, the standardisation of patient data, and the importance of systematic accountability.
https://resource.ddregpharma.com/blogs/gidh-who-global-strategy-digital-health-2027/

📢 DDReg Knowledge Capsule – Episode [28]This podcast covers the analysis of the regulatory complexities involved when relocating production facilities for pharmaceuticals, biologics, and medical devices. Moving a manufacturing site is not a simple logistical task but a significant material change that requires specific approvals and notifications across different global jurisdictions. The text highlights critical compliance pillars, such as rigorous process validation, the integration of quality management systems, and the strategic timing of submissions to avoid supply chain gaps. It also outlines the severe financial and legal risks associated with inadequate transition management, including product recalls and regulatory sanctions.https://resource.ddregpharma.com/blogs/regulatory-impact-manufacturing-site-transfers/

📢 DDReg Knowledge Capsule – Episode [27]This podcast covers Post-Market Clinical Follow-up (PMCF) under the European Union’s Medical Device Regulation (MDR). It describes how manufacturers must transition from passive monitoring to a continuous, proactive process of gathering clinical data throughout a product’s entire lifecycle. The source outlines the necessity of creating defensible documentation, specifically highlighting the PMCF Plan and the Evaluation Report as key tools for maintaining compliance. Furthermore, it details various methodologies for data collection, such as clinical investigations and registries, while emphasizing the importance of aligning these activities with risk management principles.https://resource.ddregpharma.com/blogs/post-market-clinical-follow-up-in-eu-medical-devices/

📢 DDReg Knowledge Capsule – Episode [26]This podcast cover about how ethnic sensitivity influences the creation and approval of pharmaceuticals on a global scale. It highlights that biological differences, such as genetics and metabolism, alongside extrinsic factors like diet and environment, can significantly alter a medication’s safety and performance. To address these variations, regulatory bodies follow specific international guidelines to determine if clinical data from one region can be applied to another.https://resource.ddregpharma.com/blogs/ethnic-sensitivity-in-drug-development/

📢 DDReg Knowledge Capsule – Episode [25]This podcast cover about ICH E5 guidelines mandate bridging studies when foreign clinical data cannot reliably predict a drug's safety or efficacy in a local population. Requirements depend on ethnic sensitivity, including intrinsic genetic factors, extrinsic medical practices, and PK/PD differences.https://resource.ddregpharma.com/blogs/bridging-studies-mandatory-under-ich-e5/

📢 DDReg Knowledge Capsule – Episode [24]How cultural influences create significant discrepancies in adverse event reporting and patient-reported outcomes within global pharmacovigilance. It highlights that inconsistencies in safety data often stem from social norms, language barriers, and varying levels of health literacy rather than just regulatory failures. The source warns that these nuances can lead to biased datasets, potentially complicating regulatory inspections and drug approvals. To mitigate these risks, the author suggests implementing culturally adapted tools, enhanced patient education, and digital reporting systems. Ultimately, the article argues that integrating cultural intelligence into clinical research is essential for ensuring the accuracy and reliability of global medical safety signals.https://resource.ddregpharma.com/blogs/cultural-nuances-in-adverse-event-reporting/

📢 DDReg Knowledge Capsule – Episode [23]importance of maintaining rigorous oversight of external vendors within the international pharmaceutical and medical device sectors. It explains that regulatory bodies hold the primary product owners directly accountable for any quality failures, regardless of where manufacturing or material sourcing occurs. To mitigate these risks, the source advocates for a structured governance model that uses risk-based assessments to determine the intensity and frequency of supplier evaluations. Furthermore, it details how formal quality agreements, comprehensive audits, and continuous performance tracking are essential tools for ensuring global compliance. Ultimately, the text asserts that integrating digital quality systems and expert-led monitoring is necessary to satisfy legal requirements and protect patient safety.
https://resource.ddregpharma.com/blogs/managing-supplier-compliance-and-audits-across-global-networks/